Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Albiglutide Fragment (GLP-1 fragment 7-36) is one copy of the 30-amino-acid sequence of modified human glucagon-like peptide-1 (GLP-1, fragment 7-36). The albumin section, which can be found in the entire sequence of albiglutide (trade names Eperzan, Tanzeum, GSK-716155, GSK716155, albugon), a strong and long-acting GLP-1 agonist licensed for the treatment of type 2 diabetes/T2DM, is absent from Albiglutide Fragment. GSK developed and marketed albiglutide under the trade names Tanzeum and Eperzan in the US and EU, respectively, as an anti-diabetic/anti-hyperglycemic medication. Albiglutide is a peptide made up of 17 disulfide bridges and 645 proteinogenic amino acids. The modified human GLP-1 consists of two copies, amino acids 1–30 and 31–60, where glycine has been substituted for alanine at position 2 to improve resistance to DPP-4. The human albumin sequence is what's left. In the event that metformin therapy is ineffective or intolerable, albiglutide can be used either alone or in conjunction with other antidiabetic medications, such as insulins. Although it is unclear as of 2018 if albiglutide affects a person's risk of dying, GSK has stated that it plans to remove the medication from the global market by July 2018 due to financial concerns.
Targets |
GLP-1 receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C148H224N40O45
|
|
---|---|---|
Molecular Weight |
3283.6
|
|
CAS # |
782500-75-8
|
|
Related CAS # |
Albiglutide fragment TFA; Albiglutide fragment; 224638-84-0
|
|
SMILES |
O=C([C@H](CC(C)C)NC([C@H](CC1=CNC2C=CC=CC1=2)NC([C@@H](C)NC([C@H]([C@H](C)CC)NC([C@H](CC1C=CC=CC=1)NC([C@H](CCC(=O)O)NC([C@H](CCCCN)NC([C@@H](C)NC([C@@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(=O)O)NC([C@H](CC(C)C)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(=O)O)NC([C@H](CO)NC([C@H]([C@H](C)O)NC([C@H](CC1C=CC=CC=1)NC([C@@H]([C@H](C)O)NC(CNC([C@H](CCC(=O)O)NC(CNC([C@H](CC1=CN=CN1)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N[C@H](C(N[C@H](C(NCC(N[C@H](C(N)=O)CCCNC(=N)N)=O)=O)CCCCN)=O)C(C)C
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL | |
5 mM | 0.0609 mL | 0.3045 mL | 0.6091 mL | |
10 mM | 0.0305 mL | 0.1523 mL | 0.3045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.